Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Head-to-head evidence comparison — which supplement is right for you?
Clascoterone vs Tazarotene: Clascoterone has the stronger overall evidence (7 vs 7.5/10); they're alternatives for clearer skin (acne) — the best pick depends on your goals. Take the 2-minute quiz for a pick tailored to your goals.
Clascoterone wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (2)
Outcomes where both Clascoterone and Tazarotene have evidence — compare verdict strength side-by-side.
A source-matched dose range is not available for this product and use.
If this treatment was prescribed for you, follow your prescriber’s directions. Do not change prescribed treatment because this page has no matched dose range.
Morning and evening
Clascoterone 1% cream
A source-matched dose range is not available for this product and use.
If this treatment was prescribed for you, follow your prescriber’s directions. Do not change prescribed treatment because this page has no matched dose range.
Evening
Tazarotene 0.045% lotion
immediate
12 weeks
12 weeks
1-4 weeks
immediate
12 weeks
24 weeks
1-4 weeks
Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials
JAMA Dermatol (2020) · RCT · n=1440
The pivotal registration trials: two identical phase 3 studies, 1440 patients randomised, conducted November 2015 to April 2018.
Efficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris
J Drugs Dermatol (2023) · RCT · n=1421
709 patients received clascoterone and 712 received vehicle in the pooled ≥12-year population.
Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: A systematic review and meta-analysis of randomized placebo-controlled trials
Dermatol Ther (2021) · Meta-Analysis · n=2457
Five trials, 2457 patients (1357 clascoterone, 1100 placebo), overall low risk of bias.
Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials
J Drugs Dermatol (2020) · RCT · n=1614
The two identical phase 3 registration trials for the 0.045% lotion — 1614 subjects aged 9 and older.
New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis
J Drugs Dermatol (2020) · RCT · n=684
A pooled paediatric SUBGROUP analysis of the two phase 3 trials, not a separate trial: 136 patients aged 10-13 and 548 aged 14-17.
Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial
Arch Dermatol (2002) · RCT · n=563
The long photodamage trial: 24 weeks double-blind, then a 28-week open-label extension — 12 months in total, 563 patients.
Clascoterone has a higher evidence score (7/10 vs 7.5/10) and wins in 2 of 3 categories.
For clearer skin (acne), Clascoterone has a higher relevance score (92 vs 88).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.